Search for Clinical Trial Results

Sponsored By

Acral Lentiginous Melanoma - 12 Studies Found

Status Study
Recruiting Study Name: Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
Condition: Acral Lentiginous Melanoma
Date: 2016-08-07
Interventions: Drug: pembrolizumab pembrolizumab at 200mg IV infusion every 3 weeks
Not yet recruiting Study Name: A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Condition:
  • Acral Lentiginous Melanoma
  • Mucosal Melanoma

Date: 2016-11-23
Interventions:
  • Drug: Nivolumab Other Names:
Not yet recruiting Study Name: A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Condition:
  • Mucosal Lentiginous Melanoma
  • Acral Lentiginous Malignant Melanoma Date: 2011-04-13
    Interventions: Drug: nilotinib nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatm
Completed Study Name: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Condition:
  • Mucosal Lentiginous Melanoma
  • Acral Lentiginous Malignant Melanoma Date: 2007-12-18
    Interventions: Drug: Sunitinib Other Names:
    • Sutent
    • SU011248
Active, not recruiting Study Name: Dinaciclib in Treating Patients With Stage IV Melanoma
Condition:
  • Acral Lentiginous Melanoma
  • Lentigo Maligna Melanoma
  • Date: 2009-07-10
    Interventions: Drug: Dinaciclib Given IV Other Names:
Completed Study Name: Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Condition:
  • Acral Lentiginous Malignant Melanoma
  • Recurrent Melanoma
    • Date: 2007-05-03
    Interventions:
    • Drug: imatinib mesylate Given

Terminated Study Name: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Condition:
  • Acral Lentiginous Malignant Melanoma
  • Lentigo Maligna Malignant
    Date: 2010-05-07
    Interventions:
    • Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097

Completed Study Name: AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Condition:
  • Acral Lentiginous Malignant Melanoma
  • Ciliary Body and Choroid M
    Date: 2005-10-20
    Interventions: Drug: cediranib maleate Given orally Other Name: AZD
Terminated Study Name: Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
Condition: Melanoma
Date: 2010-03-23
Interventions:
  • Drug: Dasatinib 100 mg daily.
Completed Study Name: Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Date: 2000-04-06
Interventions:
  • Biological: adenovirus RSV-TK
  • Drug: gancic
Next >>>